Evidence map›Paper›PMID 36623286›Full record

GuidelineAnnals of internal medicine2023

Diabetes Management in Chronic Kidney Disease: Synopsis of the KDIGO 2022 Clinical Practice Guideline Update.

Sankar D Navaneethan, Sophia Zoungas, M Luiza Caramori, Juliana C N Chan, Hiddo J L Heerspink, Clint Hurst, Adrian Liew, Erin D Michos, Wasiu A Olowu, Tami Sadusky and 12 more

Open access · hybridAbstract readPractice Guideline
PubMed Publisher
In one paragraph

Guideline in Annals of internal medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 135 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
135citing papers in PubMed, 6 pooled it
44.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

135 citing papers in PubMed, 6 syntheses or guidelines pooled it, 221 citations in OpenAlex.

  1. Pooled it
  2. The Japanese Society of Hypertension Guidelines for the management of elevated blood pressure and hypertension 2025 (JSH2025).Hypertension research : official journal of the Japanese Society of Hypertension · 2026
    Guideline
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Review
  11. Article
  12. Observational
  13. Article
  14. Article
  15. Observational
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

75 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors at 18 institutions in 11 countries.

Sankar D NavaneethanSection of Nephrology, Department of Medicine, Selzman Institute for Kidney Health, Baylor College of Medicine, Institute of Clinical and Translational Research, Baylor College of Medicine, and Section of Nephrology, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas (S.D.N.).
Sophia ZoungasSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia (S.Z.).ORCID 0000-0003-2672-0949
M Luiza CaramoriDepartment of Endocrinology and Metabolism, Cleveland Clinic Foundation, Cleveland, Ohio, and Division of Diabetes, Endocrinology and Metabolism, University of Minnesota, Minneapolis, Minnesota (M.L.C.).
Juliana C N ChanDepartment of Medicine and Therapeutics, Hong Kong Institute of Diabetes and Obesity, and Li Ka Shing Institute of Health Science, The Chinese University of Hong Kong, Hong Kong, China (J.C.N.C.).ORCID 0000-0003-1325-1194
Hiddo J L HeerspinkDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands (H.J.L.H.).ORCID 0000-0002-3126-3730
Clint HurstHouston, Texas (C.H.).
Adrian LiewThe Kidney & Transplant Practice, Mount Elizabeth Novena Hospital, Singapore (A.L.).ORCID 0000-0002-0963-6270
Erin D MichosDivision of Cardiology, Johns Hopkins University School of Medicine, Baltimore, Maryland (E.D.M.).ORCID 0000-0002-5547-5084
Wasiu A OlowuPediatric Nephrology and Hypertension Unit, Obafemi Awolowo University Teaching Hospitals Complex, Ile-Ife, State of Osum, Nigeria (W.A.O.).
Tami SaduskySeattle, Washington (T.S.).
Nikhil TandonDepartment of Endocrinology and Metabolism, All India Institute of Medical Sciences, New Delhi, India (N.T.).ORCID 0000-0003-4604-1986
Katherine R TuttleDivision of Nephrology, University of Washington, Spokane, Washington (K.R.T.).ORCID 0000-0002-2235-0103
Christoph WannerDivision of Nephrology, University Hospital of Würzburg, Würzburg, Germany (C.W.).ORCID 0000-0001-9507-5301
Katy G WilkensNutrition and Fitness Services, Northwest Kidney Centers, Seattle, Washington (K.G.W.).
Jonathan C CraigCollege of Medicine and Public Health, Flinders University, Adelaide, South Australia, and Cochrane Kidney and Transplant, Sydney, New South Wales, Australia (J.C.C.).ORCID 0000-0002-2548-4035
David J TunnicliffeCochrane Kidney and Transplant and Sydney School of Public Health, The University of Sydney, Sydney, New South Wales, Australia (D.J.T.).ORCID 0000-0003-3270-3475
Marcello TonelliDepartment of Medicine, University of Calgary, Calgary, Alberta, Canada (M.T.).ORCID 0000-0002-0846-3187
Michael CheungKDIGO, Brussels, Belgium (M.C., A.E.).ORCID 0000-0002-6233-2831
Amy EarleyKDIGO, Brussels, Belgium (M.C., A.E.).ORCID 0000-0003-3200-2492
Peter RossingSteno Diabetes Center Copenhagen and University of Copenhagen, Copenhagen, Denmark (P.R.).ORCID 0000-0002-1531-4294
Ian H de BoerKidney Research Institute, University of Washington, Seattle, Washington (I.H.B.).ORCID 0000-0003-1571-7592
Kamlesh KhuntiDiabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, United Kingdom (K.K.).
All India Institute of Medical Sciences · INChinese University of Hong Kong · HKFlinders University · AUJohns Hopkins University · USLeicester General Hospital · GBMichael E. DeBakey VA Medical Center · USMonash University · AUMount Elizabeth Novena Hospital · SGNorthwest Kidney Centers · USObafemi Awolowo University Teaching Hospitals Complex · NGThe University of Sydney · AUUniversitätsklinikum Würzburg · DEUniversity Medical Center Groningen · NLUniversity of Calgary · CAUniversity of Copenhagen · DKUniversity of Minnesota · USUniversity of Washington · USWashington State University Spokane · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

descriptionThe KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease is an update of the 2020 guideline from Kidney Disease: Improving Global Outcomes (KDIGO).

methodsThe KDIGO Work Group updated the guideline, which included reviewing and grading new evidence that was identified and summarized. As in the previous guideline, the Work Group used the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach to appraise evidence and rate the strength of recommendations and expert judgment to develop consensus practice points. New evidence led to updating of recommendations in the chapters Comprehensive Care in Patients With Diabetes and CKD (Chapter 1) and Glucose-Lowering Therapies in Patients With T2D and CKD (Chapter 4). New evidence did not change recommendations in the chapters Glycemic Monitoring and Targets in Patients With Diabetes and CKD (Chapter 2), Lifestyle Interventions in Patients With Diabetes and CKD (Chapter 3), and Approaches to Management of Patients With Diabetes and CKD (Chapter 5). RECOMMENDATIONS: The updated guideline includes 13 recommendations and 52 practice points for clinicians caring for patients with diabetes and chronic kidney disease (CKD). A focus on preserving kidney function and maintaining well-being is recommended using a layered approach to care, starting with a foundation of lifestyle interventions, self-management, and first-line pharmacotherapy (such as sodium-glucose cotransporter-2 inhibitors) demonstrated to improve clinical outcomes. To this are added additional drugs with heart and kidney protection, such as glucagon-like peptide-1 receptor agonists and nonsteroidal mineralocorticoid receptor antagonists, and interventions to control risk factors for CKD progression and cardiovascular events, such as blood pressure, glycemia, and lipids.

Indexed as

Diabetes Mellitus, Type 2Renal Insufficiency, ChronicSodium-Glucose Transporter 2 InhibitorsGlucoseHumansKidneyGlucoseSodium-Glucose Transporter 2 Inhibitors

Identifiers

PMID36623286
OpenAlexW4313855017

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.